

1 DNA aptamers for the recognition of HMGB1 from *Plasmodium*
2 *falciparum*.

3

4 Diego F. Joseph¹, Jose A. Nakamoto¹, Oscar Andree Garcia Ruiz¹, Katherin Peñaranda^{1,2},
5 Ana Elena Sanchez-Castro¹, Pablo Soriano Castillo¹, and Pohl Milón^{1,2,*}

6

7 ¹Laboratory of Applied Biophysics and Biochemistry, Centre for Research and Innovation,
8 Health Sciences Faculty, Universidad Peruana de Ciencias Aplicadas (UPC), Lima 15067,
9 Perú

10 ² Research and Innovation Division, BDM, Lima 15074, Perú

11 *Correspondence to: pmilon@upc.edu.pe

12

13

14

15

16

17

18

19

20 **Abstract**

21 Rapid Diagnostic Tests (RDTs) for malaria are restricted to a few biomarkers and antibody-
22 mediated detection. However, the expression of commonly used biomarkers varies
23 geographically and the sensibility of immunodetection can be affected by batch-to-batch
24 differences or limited thermal stability. In this study we aimed to overcome these limitations
25 by identifying a potential biomarker and by developing molecular sensors based on aptamer
26 technology. Using gene expression databases, ribosome profiling analysis, and structural
27 modeling, we find that the High Mobility Group Box 1 protein (HMGB1) of *Plasmodium*
28 *falciparum* is highly expressed, structurally stable and steadily present along all blood-stages
29 of *P. falciparum* infection. To develop biosensors, we used *in vitro* evolution techniques to
30 produce DNA aptamers for the recombinantly expressed HMG-box, the conserved domain
31 of HMGB1. An evolutionary approach for evaluating the dynamics of aptamer populations
32 suggested three predominant aptamer motifs. Representatives of the aptamer families were
33 tested for binding parameters to the HMG-box domain using microscale thermophoresis and
34 rapid kinetics. Dissociation constants of the aptamers varied over two orders of magnitude
35 between nano- and micromolar ranges while the aptamer-HMG-box interaction occurred in
36 less than 30 seconds. The specificity of aptamer binding to the HMG-box of *P. falciparum*
37 compared to its human homolog depended on pH conditions. Altogether, our study proposes
38 HMGB1 as a potential biomarker and a set of sensing aptamers that can be further developed
39 into rapid diagnostic tests for *P. falciparum* detection.

40

41

42

43

44

45

46 **Introduction**

47 Malaria is an infectious disease that affects animals and humans, caused by protozoans of the
48 genus *Plasmodium*. Malaria remains the cause of 435,000 deaths worldwide, with 219
49 million cases reported during 2017 [1]. Accurate treatment requires the identification of the
50 parasite of the genus *Plasmodium*, in addition to the species causing the disease. Currently,
51 there are several methods to diagnose malaria, such as PCR-based, Giemsa microscopy, and
52 Rapid Diagnostic Tests (RDTs). Among these options, the last two appear to be suitable for
53 low-income and mostly affected countries; nonetheless, they also present certain limitations
54 [2].

55 Giemsa microscopy is inexpensive to perform, can differentiate malaria species and stages,
56 and can quantify the parasites [2]. However, well-trained personnel is required and,
57 frequently unavailable in low-income countries [2]. RDTs, on the other hand,
58 detect *Plasmodium spp.* biomarker antigens in a small amount of blood using immobilized
59 antibodies. The two most used biomarkers are histidine-rich protein 2 (HRP-2) and lactate
60 dehydrogenase (LDH), which have been shown of high sensitivity and specificity for
61 detecting *P. falciparum* [3]. However, *P. falciparum* strains lacking the HRP-2 and HRP-3
62 genes have appeared, increasing false negative results [4,5].

63 Additionally, the production of sensing antibodies requires advanced facilities to ensure both,
64 reproducibility and consistency between batches. This limitation is aggravated by delivery

65 logistics to the final user where transportation and temperature conditions affect the
66 efficiency, sensibility, and specificity of RDTs. Although RDTs continue being the best
67 alternative for rapid screening and detection of malaria in low-income countries, they require
68 novel biomarkers for *Plasmodium spp.* to overcome the detection of false negatives and the
69 development of sensing molecules that are more reproducible and thermostable.

70 Recent genomic, transcriptomic, and proteomic studies of *Plasmodium spp.* are a great source
71 to identify potential new and abundant biomarkers [6-8]. In this context, ribosome profiling
72 (RP) appears to fill the gap between transcriptomics and proteomics [9]. RP evaluates mRNA
73 expression and estimates the ribosomal load of each particular mRNA [9]. Thus, RP allows
74 the researcher to identify which genes are expressed at any given conditions and, at the same
75 time, RP estimates the relative protein abundance potential. In the context of biomarker
76 discovery, RP arrives as a valid alternative to identify proteins that are highly synthesized in
77 the cell.

78 Aptamers offer a valid alternative for the development of biosensors as they overcome such
79 immunogenic requirement of antibodies [10]. Additionally, aptamers are chemically
80 synthesized which leads to the substantial reduction of variability between production batches
81 [10]. Aptamers, identified through Systematic Evolution of Ligands by Exponential
82 enrichment (SELEX) [11,12], have shown additional and significant advantages over
83 antibodies without compromising binding and biochemical specificity parameters [10].
84 Aptamers for malaria detection have been successfully developed for the commonly used
85 biomarkers HRP-2 and LDH [13-15]. Here, we use gene expression databases and recent RP
86 reports to identify a potential new biomarker for the detection *Plasmodium spp.*,
87 recombinantly produce it to purity, and develop high-affinity aptamers as biosensors.

88 Altogether, our study proposes a novel biomarker and a set of biosensors that can further be
89 developed into RDTs for *Plasmodium spp.* detection.

90 **Material and Methods**

91 **Biomarker selection**

92 Translational gene expression regulation, as assessed by RP on asexual blood stages, were
93 primarily used to identify highly translated mRNAs [8]. RNA-seq on all blood stages of *P.*
94 *falciparum* were compared using PlasmoDB search tools [8,16,17]. Genes whose
95 transcription was homogenous and constant among all blood stages of *P. falciparum* were
96 selected. The corresponding proteins were probed for the availability of three-dimensional
97 structures or the potential to be predicted. Proteins without atomic resolution or predicted
98 structures were excluded as available structural reports show that aptamers bind to tertiary
99 folds of proteins [18]. Protein stability and solubility, as well as the presence of
100 transmembrane domains, were estimated using the ExPASy ProtParam tool (Swiss Institute
101 of Bioinformatics, Switzerland) and TMHMM 2.0 (Center for Biological Sequence Analysis,
102 Technical University of Denmark, DK). The human homolog of HMGB1 was used for
103 negative selection steps. HMGB1 contains the HMG-box, which is a conserved domain
104 among eukaryotes [19]. Both conserved domains, from *Plasmodium falciparum* or *Homo*
105 *sapiens*, are subsequently going to be called HMG-box *Pf* and HMG-box *Hs*, respectively.
106 Clustal Omega (EMBL-EBI, UK) was used to compare HMG-box *Pf* and HMG-box *Hs* by
107 multiple sequence alignment analysis between these two domains [20].

108 **Oligonucleotides, cloning, expression, and purification of HMG-box domain**

109 Oligonucleotides, unmodified or chemically modified with fluorescein, were synthesized by
110 Macrogen (Korea). DNA sequences coding for HMG-box *Pf* and *Hs* were cloned into the
111 plasmid pET-24c (+) (KanR) by GenScript (USA). The coding sequences of both domains
112 were optimized for codon usage of the host (*E. coli* BL21) using OptimumGene™
113 (GenScript, USA) and a His-Tag was added at the carboxyl end for further purification. *E.*
114 *coli* BL21 (DE3) were made competent and transformed using Mix & Go *E.*
115 *coli* Transformation Kit & Buffer Set (Zymo Research, USA). Transformed *E. coli* were
116 cultured in Terrific Broth (yeast extract 24 g/L, tryptone 20 g/L, KH₂PO₄ 0.017 M, K₂HPO₄
117 0.072 M) medium at 37°C until the absorbance at 600 nm reached 0.5. Then, Isopropyl β-D-
118 1-thiogalactopyranoside (IPTG) 1 mM was added to induce protein expression and
119 incubation continued for three hours. After incubation, the culture was centrifuged at 6,000
120 g for 20 min at 4 °C. Then, the supernatant was discarded, and the pellet was resuspended
121 using HAKM₁₀ Buffer (50 mM HEPES (pH 7.4), 70 mM ammonium acetate, 30 mM NaCl,
122 10 mM MgCl₂, 6 mM 2-mercaptoethanol). Cells were pelleted again before lysis with using
123 5 mL BugBuster® Master Mix (EMD Millipore, USA) for each gram of cells. After
124 resuspension and incubation at room temperature for 20 minutes, the lysate was centrifuged
125 at 12,000 g for 40 min at 4 °C. The supernatant was collected for purification using a 1 mL
126 His Trap™ FF Crude Column containing Ni-NTA (GE Healthcare, USA). Briefly, the
127 column was equilibrated using five volumes of His-Tag Buffer with 10 mM imidazole (20
128 mM sodium phosphate (pH 7.4), 0.5 M NaCl). Then, the collected supernatant was loaded
129 into the column followed by three volumes of His-Tag Buffer containing 30 mM imidazole
130 to remove nonspecific bound proteins. Finally, HMG-box was eluted with five volumes of

131 His-Tag Buffer containing 300 mM imidazole. 1 mL fractions were collected independently
132 and analyzed by SDS-PAGE electrophoresis (18% acrylamide) and Coomassie blue staining.
133 Eluted proteins were dialyzed using a 3 kDa membrane D-Tube Dialyzer (Merck, Germany)
134 to remove the imidazole in Storage Buffer (200 mM ammonium acetate, 50 mM HEPES, 6
135 mM 2-Mercaptoethanol, 10% glycerol, pH 7.1). Protein purity was assessed by (18%
136 acrylamide) SDS-PAGE electrophoresis and Coomassie blue staining.

137 **Protein labeling**

138 HMG-box *Pf* and *Hs* preparations were labeled with NHS-Biotin for SELEX rounds or with
139 NHS-Atto540Q essentially as described in [21]. Protein preparations were dialyzed using
140 NHS Labeling Buffer (200 mM NaCl, 50 mM HEPES, 6 mM 2-Mercaptoethanol, 5%
141 Glycerol, pH 7.8) to remove primary amines. Labeling reactions were performed using a 2:1
142 label to protein ratio. Reactions were incubated with moderated stirring at room temperature
143 for 1 hour. After incubation, non-protein-bound labels were quenched using Glycine in a final
144 concentration of 25 mM. Labeled proteins were purified using His Trap™ FF Crude Column
145 containing Ni-NTA (as described above) and dialyzed in Storage Buffer.

146 **SELEX**

147 SELEX was performed using a 40-mer ssDNA random library (Trilink Biotechnologies,
148 USA) which contained constant flanking regions: 5' TAG GGA AGA GAA GGA CAT ATG
149 AT (N40) TTG ACT AGT ACA TGA CCA CTT GA 3'. Amplification primers were:
150 forward (5' TAG GGA AGA GAA GGA CAT ATG AT 3') and reverse (5' TCA AGT GGT
151 CAT GTA CTA GTC AA 3'). For transcription-mediated amplification of libraries, a T7
152 promoter sequence was added (T7 reverse primer: 5' TTC AGG TAA TAC GAC TCA CTA

153 TAG GGT CAA GTG GTC ATG TAC TAG TCA A 3'). Each selection round was composed
154 of: i) Aptamer selection using biotinylated HGM-box that were immobilized on streptavidin-
155 coated magnetic beads (Streptavidin Mag Sepharose™ from GE Healthcare, USA). The bead
156 binding capacity for either HMG-box *Pf* or HMG-box *Hs* was estimated to 19 pmol/μL beads
157 slurry. Selections were performed in SELEX Buffer (100 mM NaCl, 1.5 mM KCl, 5 mM
158 MgCl₂, 6mM 2-Mercaptoethanol, 50 mM Tris HCl, pH 7.5) at 25°C with moderate and
159 continuous shaking. ii) HGM-box-bound aptamers were separated from the solution using a
160 magnet followed by resuspension using SELEX buffer and a second magnetic separation.
161 The number of bead resuspensions (washes) varied along SELEX rounds (S2 Table). iii)
162 Bound oligonucleotides were used for further regeneration of the ssDNA library by PCR
163 using Trilink forward, and T7 Trilink-modified reverse primers using the Maxima Hot Start
164 Green PCR Master Mix (2X) (Thermo Fisher Scientific, USA). iv) Resulting dsDNA were
165 used for *in vitro* transcription using the TranscriptAid T7 High Yield Transcription Kit
166 (Thermo Fisher Scientific, USA). v) *in vitro* reverse transcription was used to regenerate a
167 ssDNA pool of enriched aptamers using the RevertAid Reverse transcriptase (Thermo Fisher
168 Scientific, USA). Generally, the selection stringency was increased along cycles of SELEX
169 by modifying ionic strength, time of incubation and the number of washes (S2 Table). Purity
170 and size of dsDNA, RNA, and ssDNA was assessed by 8M UREA PAGE followed by
171 methylene blue staining. Concentration was measured by absorbance at 260 nm in a
172 Nanodrop One spectrophotometer (Thermo Fisher Scientific, USA).

173 **Diversity Visualization by Endonuclease (DiVE) assay and library enrichment**

174 DiVE protocol was standardized based on Lim *et al.* [22]. All the experiments were
175 performed using the Thermo Scientific S1 endonuclease (Thermo Fisher Scientific, USA).

176 For the reaction tubes, 200 ng of double-stranded DNA (dsDNA) from each SELEX cycle
177 was used. The final volume of the reaction was 20 μ L, and each sample contained S1
178 Reaction Buffer (40 mM sodium acetate (pH 4.5), 300 mM NaCl, 2 mM ZnSO₄). Each tube
179 reaction was subjected to denaturation at 95°C for 5 minutes and reannealing at 65°C for 5
180 minutes. After that, 1 μ L of S1 endonuclease U/ μ L was added to the mixture followed by 30
181 minutes incubation at 65°C. Reactions were stopped by adding ethylene- diaminetetraacetic
182 acid (EDTA) to a final concentration of 2 mM (pH 8.0). Finally, 5 μ L of each sample was
183 mixed with 1 μ L of RunSafe (Cleaver Scientific, UK) and visualized in a 2% agarose gel.
184 Low diversity samples appeared as defined bands of the expected DNA length while high
185 diversity samples appeared as smears or were absent.

186 **Library sequencing**

187 Cycles four, six, eight, ten, and fourteen were taken for Next Generation Sequencing as they
188 showed low (cycle four), partial (cycles six and eight) and high (cycles ten and fourteen)
189 enrichment as evaluated by DiVE. The dsDNA pools were processed as described in the 16S
190 Metagenomic Sequencing Library Preparation protocol (Illumina, USA). Briefly, 5 ng of
191 dsDNA from each selected cycle was amplified by PCR for eight cycles using forward (5'
192 TCG TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG TAG GGA AGA GAA GGA
193 CAT ATG AT 3') and reverse (5' GTC TCG TGG GCT CGG AGA TGT GTA TAA GAG
194 ACA GTC AAG TGG TCA TGT ACT AGT CAA 3') Trilink primers modified with
195 overhang adapters. After amplification, PCR products were purified with the AMPure XP
196 beads (Beckman Coulter, USA) protocol. Subsequently, sequencing indexes were added by
197 PCR, provided by the Nextera® (R) XT Index Kit (Illumina, USA). Finally, indexed PCR
198 products were purified with AMPure XP beads (Ampure, USA). Each indexed PCR product

199 was quantified by absorbance at 260 nm and diluted to a final concentration of 4 nM using
200 10 mM Tris (pH 8.5). Five microliters of each indexed PCR were mixed to obtain the pooled
201 library. Finally, the pooled library was denatured using an equal volume of 0.2 N NaOH,
202 incubated and room temperature for 5 minutes and diluted again to a final concentration of 4
203 pM using HT1 Buffer (Illumina, USA) and loaded into the MiSeq Reagent Nano Kit v2
204 cartridge (Illumina, USA) for 300 reading cycles.

205 **Bioinformatic analysis and aptamer selection**

206 For a primary analysis of the sequences and a comparison between SELEX cycles, the
207 bioinformatic toolkit FASTAptamer was employed [23]. Reverse data retrieved by
208 sequencing was reverse complemented and mixed with the forward data to obtain a collection
209 of sequences comprising both sequencing steps. The FASTAptamer Count command allowed
210 to estimate the frequency for all sequences in each SELEX cycle. Subsequently, the
211 FASTAptamer Enrich command was used to estimate the relative increase in abundance
212 between subsequent SELEX cycles for each sequence analyzed. Candidate molecules were
213 ranked depending on the enrichment between cycles and abundance. The MEME Suite and
214 Clustal Omega (EMBL-EBI) was used to evaluate the presence of conserved motifs [20,24].
215 Mfold was used to determine the Gibbs free energy of potential secondary structures using
216 the selection conditions, 25°C, 100 mM Na⁺, and 3 mM Mg⁺² [25]. Conserved flanking
217 regions of the aptamer library were included in the analysis.

218 **Three-dimensional structure modeling and docking predictions**

219 Modeling of three-dimensional (3D) structures of aptamers followed the principles described
220 by Jeddi *et al.* [26]. Briefly, the Mfold web server was employed to predict secondary

221 structures of the aptamers as described above. Output files were saved using the Vienna
222 bracket format [25]. A 3D equivalent single-stranded RNA (ssRNA) model was built for each
223 aptamer through the RNAComposer web server, using the bracket structures previously
224 obtained [27]. The 3D ssRNA models were manually transformed into ssDNA structures
225 using the molefacture and the autoPSF plugin of VMD software [28]. This was achieved by
226 replacing the H5 atom in each uracil residue with a methyl moiety, manually replacing the
227 uracil denomination with thymine in the PDB file, and changing the ribose to deoxyribose
228 with the autoPSF builder [26]. Then, we used VMD and NAMD to refine the new 3D DNA
229 structures in an ionized (100 mM NaCl) water box through 10,000 iterations of energy
230 minimization [29,30]. The 3D structure of HMG-box *Pf* was built using homology modeling
231 with the SWISS-MODEL Suit ([31]. Finally, the ZDOCK server was employed to predict
232 the structural interaction between the aptamers and the HMG-box *Pf* [32]. We used the
233 ZDOCK server with ZDOCK 3.0.2 without specifying specific interactions.

234 **Determination of dissociation constants**

235 Dissociation constants were measured using Microscale Thermophoresis (MST) on a
236 Monolith NT.115 instrument (NanoTemper, Germany). Thermal migrations were monitored
237 in real time by using a FAM-labeled probe (probe^{FAM}) annealed to the 5' end of the aptamer.
238 Pre-annealing of the probe to the aptamer was performed by mixing aptamers with probe^{FAM}
239 in 4:1 ratio followed by 5 min denaturation at 95°C and 20 min renaturation at room
240 temperature. Reactions (20 µL) were prepared containing 50 nM of aptamers and varying
241 concentrations of either HMG-box *Pf* or *Hs*. Before measuring, samples were centrifuged at
242 14,000 g for 5 min. The reactions were loaded into MO-K022 standard capillaries
243 (NanoTemper, Germany) and measured. A preliminary fluorescence scan of capillaries was

244 used to assess homogeneity within the titration. Reactions were excluded if a fluorescence
245 difference between scans was higher than 10%. Time courses of fluorescence measurements
246 were set 5 seconds with the infrared (IR) laser off, 30 seconds with the IR on, and 5 seconds
247 off. A delay of 25 seconds between reads was used for thermal equilibration of the
248 instrument. All reactions were performed in PBS at room temperature. IR laser power was
249 set to 20% while fluorescence excitation power was set to 20% to 70% according to the
250 dynamic of each aptamer.

251 **Kinetic Experiments**

252 To measure the kinetics of aptamer-protein interactions an SX20 stopped-flow apparatus was
253 used (Applied Photophysics, UK). All reactions were performed in SELEX Buffer (pH 7.4).
254 Aptamers, PfR6 and PfE3, were pre-annealed to the probe^{FAM} as described above and called
255 from herein, PfR6^{FAM} and PfE3^{FAM}. Fluorescent measurements were carried out at 22 °C
256 using a monochromatic light source (470 nm) powered with 10 mA. Emitted fluorescence
257 was measured with photomultipliers set at 320 V after passing a long-pass filter with a cut-
258 off of 515 nm essentially as described in [33]. Equal volumes (60 µL) of each reactant were
259 rapidly mixed and fluorescence changes over time were measured. Typically, one solution
260 contained aptamer (0.25 µM), probe^{FAM} (0.2 µM) while the second solution was composed
261 of 1 µM HMG-box^{540Q} *Pf* or *Hs*, quenching derivatives of their respective proteins labeled
262 with Atto-540Q. Between 7 to 10 replicates were measured. Every single measurement
263 acquired 1,000 data points in a logarithmic sampling mode. Apparent rate constants were
264 estimated by non-linear regression with exponential equations using Prism 7.02 (Graphpad
265 Software, USA). Averaged rate constants were calculated as described in [34].

266 **Results**

267 **HMGB1 as a biomarker for *Plasmodium* detection**

268 Recent advancements in the ‘omics field allow novel approaches to assess gene expression
269 regulation at several stages, namely, gene transcription, mRNA translation and protein
270 availability in the cell. Among these, translation regulation can be studied by RP, which
271 provides unprecedented parameters, both qualitative and quantitative [35]. At any given cell
272 growth state, RP can relatively estimate the ribosome load for each identified mRNA [35].
273 Recent applications of RP for *P. falciparum* identified more than 3,000 actively translated
274 mRNAs at different stages of parasite life-cycle [8]. Actively translated mRNAs shall result
275 in highly expressed proteins, an appealing feature to propose new potential biomarkers as
276 parasite density can be estimated. Using the freely available RP databases, biomarker
277 candidates were ranked according to their expression in the merozoite blood-stage, as being
278 the stage with the most active protein synthesis apparatus (Fig 1A). Any gene whose
279 expression was null during any blood stage was excluded since homogenous expression
280 during all blood stages was desired. To assess the expression variability along blood-stages
281 of *P. falciparum* the most expressed genes from RP datasets were validated by transcriptomic
282 reports using PlasmoDB [16,17]. Candidates whose expression was not uniform during all
283 blood stages were eliminated. Biomarker candidates that met both selection criteria, being
284 abundant and showing similar expression patterns during all blood stages of the parasite,
285 were pre-selected (Fig 1).

286

287 **Fig 1. HMG-box as a potential biomarker of *Plasmodium falciparum*.**

288 (A) Workflow for the identification of highly abundant proteins of *Plasmodium falciparum*
289 as novel biomarker candidates. (B) Structure predictions by homology of HMG-box from *P.*
290 *falciparum* and its human homolog using the Swiss-model suite [31]. (C) BLASTp suite of
291 HMG-box *Pf* shows a high percentage of identity with other pathogenic *Plasmodium* species.
292 (D) Clustal Omega (EMBL-EBI, UK) multiple sequence alignment for HMG-box *Pf* and
293 HMG-box *Hs*. Both domains have 71 amino acids and share 39.4 % of identity and 54.9% of
294 similarity.

295 Further bioinformatic analysis allowed to investigate structural features of the potential
296 biomarkers. From the top five biomarker candidates, only fructose-bisphosphate aldolase
297 (FBPA) had a known 3D structure (PDB 1A5C) [36]. However, the tertiary structure of
298 HMGB1, eIF1, Tetraubiquitin, 14-3-3 protein was available from modeling based on proteins
299 from other species that shared at least 40% of their amino acid sequence (Plasmo DB, [16]).
300 From the five potential biomarkers of *P. falciparum*, HMGB1 showed up as being abundant,
301 steady along all blood-stages of the parasite and, folding into a stable tertiary structure (Fig
302 1B). Therefore, HMGB1 displays substantial premises for the development of molecular
303 sensors for *Plasmodium* detection. The HMGB1 protein from *Plasmodium spp.* has a human
304 homolog, and both contain a DNA binding domain, HMG-box (Fig 1B) [19]. Furthermore,
305 the HMG-box domain is highly conserved among *Plasmodium* species that infect humans,
306 such as *P. vivax* (88% identity), *P. knowlesi* (87% identity), *P. malarie* (85% identity), and
307 *P. ovale* (81% identity) (Fig 1C). Of particular importance, HMG-box *Pf* shows limited
308 identity (39.4 %) with HMG-box *Hs* (Fig 1D). Altogether, abundance, availability during all
309 infectious stages of the parasite, and low identity with the human counterpart make the HMG-
310 box an appealing biomarker to develop new biosensors.

311 **Aptamers against HMG-box *Pf***

312 In order to select molecular sensors that can specifically recognize the HMG-box *Pf*, we used
313 Systematic Evolution of Ligands by Exponential Enrichment (SELEX) combined with next-
314 generation sequencing (NGS). SELEX allows to *in vitro* select single-stranded
315 oligonucleotides that strongly bind a given molecule [12]. These oligonucleotides are known
316 as aptamers [37] and were shown to have significant advantages over antibodies such as
317 better thermal stability and synthesis consistency between production batches without
318 compromising their binding affinities [10,38]. These characteristics are very appealing for
319 further development of aptamers into rapid diagnostic tests to be deployed in rural areas in
320 low-income countries, the most affected by Malaria. We performed fourteen SELEX cycles
321 (Fig 2A) starting from a library of ssDNA containing 40 randomized nucleotides. In order to
322 enhance the selection of tight binders, HMG-box *Pf* concentration, incubation time and
323 strength of washes varied, increasing the selection stringency along the SELEX cycles (S2
324 Table). Whereas, to increase the specificity of the potential aptamers, negative selections
325 using the human counterpart, HMG-box *Hs*, were introduced at cycles five, eight, ten, and
326 fourteen.

327

328 **Fig 2. NGS allows the identification of aptamer motifs and their evolution during** 329 **SELEX**

330 (A) Workflow of the SELEX technique and variations applied in this work. The ssDNA
331 library (N40) was incubated with the HMG-box proteins immobilized in magnetic beads.
332 After incubation, a magnet is used to separate the ssDNA molecules that bound the proteins

333 on the magnetic beads. To amplify the bound molecules a PCR using a modified reverse
334 primer with the T7 promoter region is performed. After purification, *in vitro* transcription is
335 carried out, followed by *in vitro* reverse transcription. Finally, an enriched ssDNA library is
336 generated and used for a next cycle or for sequencing. (B) Progression of enrichment along
337 steps of selection as evaluated by the DiVE technique [22]. The ratio between non-degraded
338 DNA (enriched)/total DNA was calculated from image quantifications of the resulting
339 agarose gel using the ImageJ software [39] (see material and methods). Rounds 4, 6, 8, 10
340 and 14 were chosen for NGS analysis. (C) Scheme depicting the workflow for sequence
341 analysis. (D) MEME (The MEME Suite) was used to identify the most characteristic motifs
342 in each sequenced SELEX cycle. Three motifs were the most represented in cycles 8 (motif
343 3), 10 (motif 2), and 14 (motif 1). Sequences from cycles 8 and 10 share a conserved region
344 inside motifs 3 and 2, whereas this region is lost in motif 1. No representative motif was
345 detected in cycle 4. (E) Dynamics of aptamer motifs along SELEX cycles.

346

347 It is expected that the initial variability of the starting library decreases along the SELEX
348 cycles, enriching a sub-population that contains the potential aptamers. To assess the
349 enrichment of aptamers over the high variability of the starting library, we used the DiVE
350 assay [22] and bioinformatic analysis of sequencing data (see below). DiVE uses the S1
351 endonuclease to differentiate between homoduplex and heteroduplex dsDNA by cleaving
352 short single-stranded ends, nicks, and heteroduplex loops. An enriched pool would have more
353 dsDNA homoduplex compared with a non-enriched pool. Thus, the homoduplex would not
354 be cleaved and could be visualized in an agarose gel. The DiVE assay allowed to confirm
355 enrichment at cycles eight, ten, and fourteen with a loss of homogeneity from cycle eleven

356 to thirteen (Fig 2B and S1 Fig.). The dsDNA obtained from cycles four, six, eight, ten, and
357 fourteen were used for NGS using the Illumina system.

358 Raw sequences (typically over 80,000 reads for each SELEX cycle) obtained from
359 sequencing were processed using the FASTAptamer toolkit (Fig 2C) [23]. Briefly, a FASTQ
360 file was processed using the algorithm FASTAptamer Count that ranks DNA sequences
361 based on their abundance for each SELEX cycle (Refer to S1 Data for raw ranked sequences).
362 Best ranked sequences in cycle 14 varied between 14,995 RPM (Reads per Million, a
363 normalized index for frequency) and 27,6943 RPM. In cycle ten, the most abundant
364 sequences ranged between 5,933 RPM and 103,658 RPM. Final rounds of selection provided
365 fewer sequences with higher frequency, while earlier selection cycles did not show sequences
366 over 190 RPM of representation (For raw data, refer to S2 Data). An important indicator of
367 aptamer selection can be surmised from the enrichment of each sequence along the selection
368 procedure. This can be estimated from the ratio of sequence frequencies belonging to
369 successive SELEX cycles. Thus, we used the FASTAptamer Enrich algorithm to calculate
370 the enrichment of all aptamer sequences over two SELEX cycles, i.e., fourteen over ten or
371 ten over eight. Most enriched sequences showed a frequency ratio ranging from 82 to 566 in
372 cycles fourteen over ten. The enrichment ratio for cycles ten over eight showed increased
373 enrichment ranging between 24.1 and 16.5 (See S3 Data for all sequences). Combining the
374 results from both, ranking and enrichment, nine potential aptamers were identified (Table 1).

375 **Table 1. Top-ranked and enriched sequences as evaluated by NGS.**

Name	Sequence*	ΔG (Kcal/mol)*	Ranking [§]	Enrichment [§]	K_d [¶]	Δ MST [¶]
PfR1	GAGAAGGACTGCTTAGGCTTG CGATGTGAAATCTGTAATC	-3.92	1 ₍₁₄₎	4.13 _(14/10)	175 ± 54	7.6 ± 0.6

PfR2	AGATGCAAAGGACTGCTCAG GCTTGCGATGGCAGCTTCAT	-5.72	2 ₍₁₄₎	32.05 _(14/10)	778 ± 1020	4 ± 2
PfR3	CACTAGGTCTGCTTAGGATTG CGTAAGTAAAAGTCATTTA	-6.43	3 ₍₁₄₎	566.11 _(14/10)	1930 ± 560	18 ± 3
PfR4	ACCGACTACGTCAACCTGGGT CTGCTCGGGATTGCGGATG	-6.92	1 ₍₁₀₎	8.68 _(10/8)	41 ± 11	8.6 ± 0.6
PfR5	AGCCGTGGATTGCAAAGGGCT GCTGTGGCTTAGTTGAATG	-5.33	3 ₍₁₀₎	18.38 _(10/8)	560 ± 120	8.5 ± 0.6
PfR6	CGCGTGGGTTTGGCTCCGGGC CTGGCGGATGCACGTATAG	-6.11	5 ₍₁₀₎	2.18 _(10/8)	65 ± 15	7 ± 0.6
PfE1	GCCGACTACGTCAACCTGGGT CTGCTCGGGATTGCGGATG	-7.53	4 ₍₁₀₎	24.10 _(10/8)	81 ± 20	8.8 ± 0.5
PfE2	ACCGACTACGTCAACTGGGT CTGCTCGGGATTGCGGATG	-6.92	14 ₍₁₀₎	18.58 _(10/8)	55 ± 20	7.8 ± 0.7
PfE3	AGTTTACACCAAGGACTGCTT AGGATTGCGTTAGGGTATT	-2.93	10 ₍₁₄₎	301.81 _(14/10)	815 ± 158	17 ± 0.6

376 Top-ranked and enriched sequences obtained by bioinformatic analysis. Here, we show the N40 central region of the aptamers, excluding
 377 the flanking 5' (TAGGGAAGAGAAGGACATATGAT) and 3' (TTGACTAGTACATGACCACTTGA) regions⁵. Gibbs free energy was
 378 calculated considering the flanking regions using the Mfold web server⁴ (See S3 Fig. for secondary structure predictions). Ranking and
 379 enrichment values were taken from the FASTAptamer toolkit [23]. The cycle in which the aptamer was obtained, whether by Ranking or
 380 Enrichment, is shown in parenthesis⁶. Aptamer K_d values were obtained Microscale Thermophoresis Pf⁹ (Fig 4A,B). Thermophoretic
 381 amplitude changes as an indicator of the extent of binding⁹. Mean values and standard error were calculated from three independent
 382 measurements.

383

384 Additionally, sequences from the sequential selection process were also used to select for
 385 families of aptamers sharing a common and conserved sequence with few substitutions
 386 within the sequence. The variability within each family can arise either from the original
 387 library or by synthesis errors of the Taq polymerase, T7 RNA polymerase, or retro
 388 transcriptase that were used to regenerate the pool of ssDNA. To further analyze how families
 389 are enriched along the SELEX cycles of selection, we used the FASTAptamer Cluster

390 algorithm [23] together with MEME Suite Motif Analysis and the Clustal Omega [20,24].
391 Representative motifs in cycles eight, ten, and fourteen were identified (Fig 2D). Motif 3 was
392 the most abundant in cycle eight with about 40% of share. However, motif 3 diminished in
393 cycles ten and fourteen, concomitantly with an increase of share for motif 2. A relative
394 abundance of 70 % for this family was followed by a reduction to less than 20 % in cycle
395 fourteen. On the other hand, motif 1, with low representation in cycles eight and ten, appeared
396 highly abundant in cycle fourteen, with 80 % of share (Fig 2E). Motif 1 was represented by
397 sequences PfR1, PfR2, PfR3, and PfE3. Whereas motif 2 was represented by sequences PfR4,
398 PfR5, PfR6, PfE1, and PfE2. PfR4 and PfE1 shared motif 2 and 3 within their sequences
399 (Table 1). Overall, the bioinformatic flow used here allowed to identify nine potential
400 aptamers for the HMG-box *Pf*, with three representing families of aptamers that vary their
401 relative abundances along the SELEX process (Table 1, Fig 2E).

402 **Interaction parameters between aptamers and HMG-box *Pf***

403 Nine aptamers, among the best, ranked or enriched, and belonging to either of the three most
404 represented motifs were chemically synthesized and tested for binding to the HMG-box *Pf*
405 using Microscale Thermophoresis (MST). MST allows the analysis of molecular interactions
406 by measuring drifts of fluorescent reporters that are induced by small temperature changes,
407 named thermophoresis [40,41]. The degree of thermophoresis change depends on the bound
408 and unbound state of the fluorescent reporter with the ligand. Therefore, the thermophoresis
409 changes as a function of ligand concentration allow calculating dissociation constants (K_d)
410 [40]. Several MST applications for aptamer research have been reported (see [42] for detailed
411 methods). Here, we label the aptamer with a fluorescent probe (probe^{FAM}) and use it at a
412 constant concentration and increased the concentrations of HMG-box *Pf*, ranging from 0.1

413 nM to 2 μ M. The measured affinities ranged from 50 nM to 2 μ M, with aptamers PfR1, PfR4,
414 PfR6, Pfe1, and Pfe2 being in the low nanomolar range and PfR2, PfR5, and Pfe3 in the
415 micromolar range of dissociation constants (Table 1) (Fig 3A,B). PfR6 was representative of
416 the group showing high affinities, while aptamer Pfe3 showed the greatest MST amplitude
417 at a lower affinity.

418 Another parameter to consider for optimal aptamers lays on specificity determinants. Thus,
419 we probed PfR6 and Pfe3 binding to HMG-box *Hs* by MST. The extent of binding PfR6 to
420 the human homolog of HMG-box was lower when compared to the *Plasmodium* counterpart
421 (Fig 3C). However, the Pfe3 aptamer showed residual capacity to interact with HGM-box
422 *Hs*, however with a 10-fold reduced affinity (Fig 3D). In brief, the PfR6 aptamer appears to
423 strongly interact with the HMG-box from *P. falciparum*.

424

425 **Fig 3. Aptamers efficiently bind the HMG-box from *P. falciparum***

426 MST analysis of the interaction between aptamers and HMG-box. (A) Thermophoresis
427 changes of best ranked aptamers as a function of HMG-box *Pf* concentration. (B)
428 Thermophoresis changes of the most enriched aptamers as a function of HMG-box *Pf*
429 concentration. Specificity assessment for PfR6 (C) and Pfe3 (D). The binding of each
430 aptamer to HMG-box *Pf* (open circles) was compared to the human homolog (open squares)
431 or in the absence of the aptamer (open triangles). All reactions were measured in triplicates.
432 Error bars indicate standard deviations. Continuous lines show the non-linear regression
433 using a quadratic equation, allowing to estimate a K_d values (Table 1).

434 In order to further analyze the binding determinants of the Pfr6 interaction with HMG-box
435 *Pf*, we studied the kinetics of the reaction by the Stopped-flow (SF) technique. SF allows
436 monitoring changes of fluorescence or absorbance in time and upon rapid mixing of two
437 reactants. Here we used Förster Resonance Energy Transfer (FRET) between HMG-box (*Pf*
438 or *Hs*) modified with the acceptor dye Atto540Q (from herein, HMG-box^{540Q} *Pf* or *Hs*) and
439 the Pfr6 aptamer pre-annealed with a small complementary probe labeled with Fluorescein
440 (Pfr6^{FAM}) (see material and methods). The interaction between the fluorescent aptamer and
441 the quenching HMG-box resulted in a fluorescence decrease in time, due to the quenching
442 effect induced by the vicinity of the non-emitting acceptor Atto540Q to the fluorescein
443 reporter in the aptamer. To assess the specificity of the signal, first, we mixed HMG-box^{540Q}
444 *Pf* with the fluorescent probe only (in the absence of aptamer Pfr6) and resulted in a
445 negligible fluorescence change in time, indicating low or no interaction between the reactants
446 (Fig 4A). Consistently, the mixing of Pfr6^{FAM} with the unlabeled HMG-box *Pf* did not result
447 in any fluorescence change in time. Mixing HMG-box^{540Q} *Pf* with Pfr6^{FAM} resulted in a
448 decrease of fluorescence over time, consistent with a rapid binding of Pfr6^{FAM} with HMG-
449 box^{540Q} *Pf*. Nonlinear analysis with an exponential function allowed estimating the apparent
450 average rate of the interaction, $k_{AV} = 0.58 \pm 0.01 \text{ s}^{-1}$.

451

452 **Fig 4. Kinetics of Pfr6 interaction with HMG-box**

453 HMG-box^{540Q} and Pfr6^{FAM} were used to monitor the interaction between the aptamer and
454 the protein in real-time using a stopped-flow apparatus (Applied Photophysics, UK). (A)
455 FRET between HMG-box^{540Q} and Pfr6^{FAM}. Mixing the labeled protein with the probe-bound
456 aptamer (green) resulted in a decrease of fluorescence over time, indicating that the binding

457 of both components results in the quenching of fluorescein due to its vicinity with the
458 quencher in the protein. FRET assessment controls lacking the aptamer or the quencher Atto-
459 540 in the HMG-box are shown in orange and purple traces respectively. (B) HMG-box^{540Q}
460 *Pf* (green) or HMG-box^{540Q} *Hs* (blue) comparison during the binding with Pfr6^{FAM} at pH
461 5.5. 7-10 replicates for each reaction were measured and averaged. Continuous lines show
462 the fitting with exponential functions.

463 Similar experiments using the human counterpart of the biomarker, HMG-box^{540Q} *Hs*,
464 showed variable degrees of binding as a function of pH. At pH=5.5, Pfr6 did not show any
465 binding to HMG-box^{540Q} *Hs* while the binding to the plasmodium counterpart was maintained
466 (Fig 4B). Thus, Pfr6 appears to bind specifically to HMG-box^{540Q} *Pf* at the given conditions.
467 However, the specificity of the binding was found to be perturbed by increasing the pH (S2
468 Fig.). Nonlinear regression showed an average rate constant $k_{AV} = 0.18 \pm 0.02 \text{ s}^{-1}$ for Pfr6
469 interaction with HMG-box^{540Q} *Pf*. This rate increased with pH, reaching $k_{AV} = 1.12 \text{ s}^{-1}$. Ion
470 concentrations and pH have been shown to influence the tertiary structure of aptamers,
471 therefore affecting their binding properties [43]. Altogether, our results indicate that Pfr6
472 interacts efficient- and rapidly with the HMG-box *Pf* domain and provide experimental
473 conditions where the specificity of the interaction is greatly enhanced.

474 **Structural model of the Pfr6– HMG-box *Pf* complex**

475 In order to evaluate the theoretical molecular interactions between aptamers and HMG-box
476 *Pf*, 3D models of the aptamers were generated followed by a molecular docking
477 approximation. Secondary structures of the aptamers were predicted by MFold (S3 Fig.) [25].
478 Then, the RNAComposer tool was used to generate 3D RNA models of the aptamers. The
479 resulting models were converted to DNA structures with VMD and then stabilized through

480 10,000 iterations of energy minimization as described by Jeddi I. and Saiz L. [26]. 2D and
481 3D predictions indicated that all nine aptamers showed unstructured regions at the 5' end.
482 The length of the unstructured regions varied between 10 and 26 bases (S3 and S5 Fig.). On
483 the other hand, the 3' end contained highly structured domains that included the 3' flanking
484 regions of the aptamer library (S5 Fig.). Pfr6 showed 21 (out of 86) unstructured nucleotides
485 at the 5' end. The structured 3' region showed three segments with short double-stranded
486 helices and several helix-to-helix interactions (Fig 5A). Thus, Pfr6 appears to fold into
487 significantly structured regions, at the same time, provides a long unstructured segment that
488 could be exploited to further develop diagnostic tests.

489

490 **Figure 5. Structural modeling of aptamers and the Pfr6–HMG-box *Pf* complex**

491 (A) Tertiary structure prediction of the Pfr6 aptamer. (B) Alternative models for the Pfr6–
492 HMG-box *Pf* complex as evaluated by ZDOCK [32]. The degree of opacity is proportional
493 to the ZDOCK Score (10% opacity corresponding to a score of 1350, maximum opacity
494 corresponds to a score of 1850) (S6 Fig.). (C) as B for the Pfr6–HMG-box *Hs*. The Pfr6
495 aptamer is depicted in sky blue, the HMG-box *Pf* in pale green, and HMG-box *Hs* in pink.

496

497 Modeling of the Pfr6–HMG-box *Pf* complex was performed using the predicted tertiary
498 structures of the aptamer and the protein (see above) using the ZDOCK tool [32]. We
499 generated 2,000 complexes for each aptamer and evaluated their respective docking score
500 based on rigid bodies interactions (S4 Data, S6 Fig.). The average value of the docking scores
501 did not indicate substantial differences between the selected aptamers. However, the highest

502 score varied for each aptamer, ranging from 1500 to 1850, with PfE3 and PfR6 among the
503 highest ones (S6 Fig.). Thus, *in silico* docking results appear to be consistent with the
504 biochemical data as measured by MST (Fig 3, Table 1). A comparison among the best ten
505 PfR6–HMG-box *Pf* complexes, as evaluated by the ZDOCK score, indicates that in eight out
506 ten models HMG-box *Pf* interacts with the structured region of PfR6 (Fig 5B). As a
507 comparison, the PfR6–HMG-box *Hs* complex (human counterpart) showed much lower
508 ZDOCK scores; however, the first ten models show an interaction of the protein with the
509 structured region of the aptamer (Fig 5C).

510

511 **Discussion**

512 The identification of potential biomarkers is a complex process where many factors must be
513 considered. In the case of *Plasmodium* species, an ideal biomarker should establish the
514 presence or absence of infection, determine the species involved, be detectable at low
515 concentrations, and be proportional to parasite density [44]. To account for these
516 characteristics, the successful entrepreneurship requires several experimental stages, from
517 basic research towards final clinical validations. Initial steps for biomarker selection can be
518 pursued using bioinformatic strategies, with large databases of the -omics providing valid
519 alternatives [45,46]. Genome-wide translation dynamics studies as revealed by RP, and in
520 contrast to transcriptomic approaches, offer a precise approximation for the *P. falciparum*
521 proteome [8]. Secondary analysis of RP datasets allowed selecting HGMB1 as a highly
522 expressed protein during all the blood stages of *P. falciparum* (Fig 1, S1 Table). Structural
523 stability, conservation among *Plasmodium spp.*, and diversity to human homologs provided
524 additional properties to cope for an ideal biomarker (Fig 1). Conserved regions of proteins

525 from *Plasmodium* could be exploited to generate biosensors for the genus. Conversely, non-
526 conserved regions allow generating species-specific biosensors [47]. Alternative approaches
527 for the selection of biomarkers for malaria have been described [48], leading to different
528 candidates for biomarkers, however, considering biomarker abundance shall increase the
529 detection likelihood of the corresponding biosensors. As a comparison, during merozoite
530 blood-stage, HGMB1 showed 88.45 folds more expression than the commonly used PfLDH
531 biomarker, while HRP-2 expression is null.

532 HMGB1 is a highly conserved non-histone protein among eukaryotes that binds the minor
533 groove of DNA and enhances the activity of transcription factors [49]. HMGB1 of *H. sapiens*
534 can be exported to the extracellular medium and can fulfill a role as an alarmin by being
535 involved in infectious and non-infectious inflammatory conditions [50]. *In vivo* assays
536 showed that HMGB1 *Pf* to be an inducing factor for potent pro-inflammatory processes,
537 leading to the induction of TNF- α and Nitric Oxide Synthase [49]. Both, transcriptional
538 enhancer and extracellular activities, add additional features to HMGB1 as a biomarker. One
539 can expect that *Plasmodium spp.* exploit the natural regulatory network of the human
540 HMGB1 by exporting HMGB1 *Pf*, although, to our knowledge, experimental evidence is still
541 lacking. Deletion of the HMGB2 homolog from *Plasmodium* resulted in attenuated
542 pathogenicity in mouse models [51], indicating an involvement on severe inflammatory
543 responses. Altogether, HMGB1 and HMGB2 appear to be involved in the inflammatory
544 response of the host, making the HMGB family a candidate for directed inhibitory drugs.
545 Indeed, several aptamers are currently being evaluated in clinical trials [52]. Here, we showed
546 that PfR6 tightly bind the conserved domain HMG-box displaying affinities that are
547 comparable to antibodies used as biological drugs. Besides their potential for

548 pharmacological administration, PfR6 may further be modified as a biosensor of HMGB1
549 from *P. falciparum*.

550 Aptamers for the detection of infectious diseases are of remarkably flexibility for the
551 development of diagnostic assays. Such versatility arises from uncountable chemical
552 modifications that are commercially available. Aptamer-tethered enzymes have been shown
553 of great sensibility and to differentiate *P. falciparum* from *P. vivax* in blood samples [53].
554 Additionally, the development of aptamers using species specific epitopes allowed to isolate
555 an aptamer that could accurately discriminate between the above species [47]. Aptamers
556 against PfLDH were used in impedance spectroscopy setups allowing to propose
557 electrochemical sensors that recognize the biomarker at a wide range of conditions [54].
558 Measurements of intramolecular FRET between aptamer linked dyes allowed the
559 development of aptamer beacons [55]. In this work we show that fluorescently modified
560 aptamers PfR6 and PfE3 allowed to monitor the binding to HGM-box *Pf* using two different
561 techniques, providing substantial premises to develop aptamer beacons. Indeed, stopped-flow
562 assays resulted in large FRET changes that, in principle, are compatible with further
563 developing of detection assays. Additionally, PfR6 interaction with HMG-box *Pf* is rapid,
564 taking place in less than a minute. Both, the resulting high signal and rapid binding, can allow
565 the development RDTs with lower detection times.

566 The chemical flexibility of aptamers can furthermore be exploited for binding optimization
567 and stability in complex samples such as blood, plasma, saliva, etc. Indeed, the introduction
568 of unnatural modifications can result in increased diversity, higher affinity as well as
569 providing inhibitory capabilities [56]. The introduction of a single phosphorodithioate
570 substitution resulted in a 1000-fold increase of affinity for an RNA aptamer against thrombin,

571 leading to picomolar dissociation constants [57]. PfR6 showed binding affinities in the
572 nanomolar range which could be further increased by targeted substitutions.

573 RDTs are the best alternative for rapid screening and detection of malaria in emerging
574 countries, and the present research allows to cope with two current limitations. First, HMG-
575 box *Pf*, is proposed as an alternative biomarker to the mostly available HRP and LDH.
576 Second, the development of aptamers and their fluorescent derivatives as potentially new
577 biosensors of HMG-box *Pf*. The latter can be further investigated in order to develop
578 alternative detection methods, i.e. enzyme-tethered, surface immobilized or molecular
579 beacons.

580

581 **Author contributions**

582 OAGR and PM conceived the project. DFJ, AESC, KP, OAGR, and PSC performed
583 experiments. DFJ, JAN, KP, and PM analyzed the data. PM and DFJ wrote the manuscript
584 with the inputs from all authors.

585 **Acknowledgments**

586 We are very thankful to Andrey Konevega for kindly providing access to the Microscale
587 Thermophoresis technology.

588 **Funding**

589 This work was funded by grants from Grand Challenges Canada (0692-01-10), Fondecyt
590 (038-2014-Fondecyt and 136-2016-Fondecyt), and InnóvatePerú (297-INNOVATEPERU-
591 EC-2016) to PM.

592 **Competing Interests**

593 BDM is a Startup of the Laboratory of Applied Biophysics and Biochemistry (UPC) where
594 PM owns shares. BDM is funded by the Peruvian government (136-2016-Fondecyt) and is
595 committed to develop diagnostic methods for neglected diseases.

596 **List of supporting information**

597 S1 Fig. Aptamer enrichment analysis by the DiVE assay.

598 S2 Fig. Kinetics of PfR6 interaction with HMG-box Pf and Hs at pH 7.5.

599 S3 Fig. Secondary structures of top-ranked and enriched aptamers.

600 S4 Fig. MST analysis of the aptamer-HGM-box complex formation.

601 S5 Fig. Tertiary structures of top-ranked and enriched aptamers.

602 S6 Fig. Averaged ZDOCK scores for the PfR6–HMG-box *Pf* complex.

603 S1 Data. Aptamer frequency analysis by the Fastaptamer count algorithm.

604 S2 Data. Aptamer ranking for all sequenced SELEX round.

605 S3 Data. Aptamer enrichment analysis by the Fastaptamer Enrich algorithm.

606 S4 Data. ZDOCK scores for 2,000 iterations corresponding to the nine aptamers.

607 S1 Table. Potential biomarkers for *Plasmodium falciparum* infection as proposed by the
608 algorithm in Fig 1.

609 S2 Table. Reaction conditions used in each SELEX cycle.

610

611 **References**

- 612 1. World Health Organization. World malaria report 2018. 2018 Nov pp. 1–210.
- 613 2. Wongsrichanalai C, Barcus MJ, Muth S, Sutamihardja A, Wernsdorfer WH. A
614 review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). *Am*
615 *J Trop Med Hyg.* 2007;77: 119–127.
- 616 3. Li B, Sun Z, Li X, Li X, Wang H, Chen W, et al. Performance of pfHRP2 versus
617 pLDH antigen rapid diagnostic tests for the detection of *Plasmodium falciparum*: a
618 systematic review and meta-analysis. *Arch Med Sci.* 2017;13: 541–549.
619 doi:10.5114/aoms.2017.67279
- 620 4. Cheng Q, Gatton ML, Barnwell J, Chiodini P, McCarthy J, Bell D, et al.
621 *Plasmodium falciparum* parasites lacking histidine-rich protein 2 and 3: a review and
622 recommendations for accurate reporting. *Malar J. BioMed Central;* 2014;13: 283.
623 doi:10.1186/1475-2875-13-283
- 624 5. Menegon M, L'Episcopia M, Nurahmed AM, Talha AA, Nour BYM, Severini C.
625 Identification of *Plasmodium falciparum* isolates lacking histidine-rich protein 2 and
626 3 in Eritrea. *Infect Genet Evol.* 2017;55: 131–134.
627 doi:10.1016/j.meegid.2017.09.004
- 628 6. Le Roch KG, Johnson JR, Florens L, Zhou Y, Santrosyan A, Grainger M, et al.
629 Global analysis of transcript and protein levels across the *Plasmodium falciparum*
630 life cycle. *Genome Res.* 2004;14: 2308–2318. doi:10.1101/gr.2523904
- 631 7. Bozdech Z, Mok S, Hu G, Imwong M, Jaidee A, Russell B, et al. The transcriptome
632 of *Plasmodium vivax* reveals divergence and diversity of transcriptional regulation in
633 malaria parasites. *Proc Natl Acad Sci USA.* 2008;105: 16290–16295.
634 doi:10.1073/pnas.0807404105
- 635 8. Caro F, Ahyong V, Betegon M, DeRisi JL. Genome-wide regulatory dynamics of
636 translation in the *Plasmodium falciparum* asexual blood stages. *eLife.* 2014;3: 568.
637 doi:10.7554/eLife.04106
- 638 9. Michel AM, Baranov PV. Ribosome profiling: a Hi-Def monitor for protein
639 synthesis at the genome-wide scale. *Wiley Interdiscip Rev RNA.* 2013;4: 473–490.
640 doi:10.1002/wrna.1172

- 641 10. Thiviyanathan V, Gorenstein DG. Aptamers and the next generation of diagnostic
642 reagents. Stastna M, Van Eyk JE, editors. *Proteomics Clin Appl*. 2012;6: 563–573.
643 doi:10.1002/prca.201200042
- 644 11. Oliphant AR, Brandl CJ, Struhl K. Defining the sequence specificity of DNA-
645 binding proteins by selecting binding sites from random-sequence oligonucleotides:
646 analysis of yeast GCN4 protein. *Molecular and Cellular Biology*. 1989;9: 2944–
647 2949. doi:10.1128/mcb.9.7.2944
- 648 12. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA
649 ligands to bacteriophage T4 DNA polymerase. *Science*. 1990;249: 505–510.
- 650 13. Song H-O, Lee B, Bhusal RP, Park B, Yu K, Chong C-K, et al. Development of a
651 novel fluorophore for real-time biomonitoring system. Carvalho LH, editor. *PLoS*
652 *ONE*. 2012;7: e48459. doi:10.1371/journal.pone.0048459
- 653 14. Wang W-X, Cheung Y-W, Dirkwager RM, Wong W-C, Tanner JA, Li H-W, et al.
654 Specific and sensitive detection of *Plasmodium falciparum* lactate dehydrogenase by
655 DNA-scaffolded silver nanoclusters combined with an aptamer. *Analyst*. 2017;142:
656 800–807. doi:10.1039/c6an02417c
- 657 15. Lee S, Manjunatha DH, Jeon W, Ban C. Cationic surfactant-based colorimetric
658 detection of *Plasmodium* lactate dehydrogenase, a biomarker for malaria, using the
659 specific DNA aptamer. Schallig HDFH, editor. *PLoS ONE*. 2014;9: e100847.
660 doi:10.1371/journal.pone.0100847
- 661 16. Aurrecochea C, Brestelli J, Brunk BP, Dommer J, Fischer S, Gajria B, et al.
662 PlasmoDB: a functional genomic database for malaria parasites. *Nucleic Acids*
663 *Research*. 2009;37: D539–43. doi:10.1093/nar/gkn814
- 664 17. Otto TD, Wilinski D, Assefa S, Keane TM, Sarry LR, Böhme U, et al. New insights
665 into the blood-stage transcriptome of *Plasmodium falciparum* using RNA-Seq.
666 *Molecular Microbiology*. 2010;76: 12–24. doi:10.1111/j.1365-2958.2009.07026.x
- 667 18. Gelinis AD, Davies DR, Janjic N. Embracing proteins: structural themes in aptamer-
668 protein complexes. *Curr Opin Struct Biol*. 2016;36: 122–132.
669 doi:10.1016/j.sbi.2016.01.009
- 670 19. Štros M, Launholt D, Grasser KD. The HMG-box: a versatile protein domain
671 occurring in a wide variety of DNA-binding proteins. *Cell Mol Life Sci*. 2007;64:
672 2590–2606. doi:10.1007/s00018-007-7162-3
- 673 20. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable
674 generation of high-quality protein multiple sequence alignments using Clustal
675 Omega. *Mol Syst Biol*. 2011;7: 539–539. doi:10.1038/msb.2011.75

- 676 21. Milon P, Konevega AL, Peske F, Fabbretti A, Gualerzi CO, Rodnina MV. Transient
677 kinetics, fluorescence, and FRET in studies of initiation of translation in bacteria.
678 *Meth Enzymol.* 2007;430: 1–30. doi:10.1016/S0076-6879(07)30001-3
- 679 22. Lim TS, Schütze T, Lehrach H, Glökler J, Konthur Z. Diversity visualization by
680 endonuclease: a rapid assay to monitor diverse nucleotide libraries. *Anal Biochem.*
681 2011;411: 16–21. doi:10.1016/j.ab.2010.12.024
- 682 23. Alam KK, Chang JL, Burke DH. FASTAptamer: A Bioinformatic Toolkit for High-
683 throughput Sequence Analysis of Combinatorial Selections. *Mol Ther Nucleic*
684 *Acids.* 2015;4: e230. doi:10.1038/mtna.2015.4
- 685 24. Bailey TL, Boden M, Buske FA, Frith M, Grant CE, Clementi L, et al. MEME
686 SUITE: tools for motif discovery and searching. *Nucleic Acids Research.* 2009;37:
687 W202–8. doi:10.1093/nar/gkp335
- 688 25. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction.
689 *Nucleic Acids Research.* 2003;31: 3406–3415. doi:10.1093/nar/gkg595
- 690 26. Jeddi I, Saiz L. Three-dimensional modeling of single stranded DNA hairpins for
691 aptamer-based biosensors. *Sci Rep.* 2017;7: 1178. doi:10.1038/s41598-017-01348-5
- 692 27. Popena M, Szachniuk M, Antczak M, Purzycka KJ, Lukasiak P, Bartol N, et al.
693 Automated 3D structure composition for large RNAs. *Nucleic Acids Research.*
694 2012;40: e112–e112. doi:10.1093/nar/gks339
- 695 28. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. *J Mol*
696 *Graph.* 1996;14: 33–8– 27–8.
- 697 29. MacKerell AD, Banavali N, Foloppe N. Development and current status of the
698 CHARMM force field for nucleic acids. *Biopolymers.* 2000;56: 257–265.
699 doi:10.1002/1097-0282(2000)56:4<257::AID-BIP10029>3.0.CO;2-W
- 700 30. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable
701 molecular dynamics with NAMD. *J Comput Chem.* 2005;26: 1781–1802.
702 doi:10.1002/jcc.20289
- 703 31. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al.
704 SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic*
705 *Acids Research.* 2018;46: W296–W303. doi:10.1093/nar/gky427
- 706 32. Pierce BG, Wiehe K, Hwang H, Kim B-H, Vreven T, Weng Z. ZDOCK server:
707 interactive docking prediction of protein-protein complexes and symmetric
708 multimers. *Bioinformatics.* 2014;30: 1771–1773. doi:10.1093/bioinformatics/btu097
- 709 33. Chulluncuy R, Espiche C, Nakamoto JA, Fabbretti A, Milon P. Conformational
710 Response of 30S-bound IF3 to A-Site Binders Streptomycin and Kanamycin.

- 711 Antibiotics (Basel). Multidisciplinary Digital Publishing Institute; 2016;5: 38.
712 doi:10.3390/antibiotics5040038
- 713 34. Milon P, Konevega AL, Gualerzi CO, Rodnina MV. Kinetic checkpoint at a late step
714 in translation initiation. *Molecular Cell*. 2008;30: 712–720.
715 doi:10.1016/j.molcel.2008.04.014
- 716 35. Ingolia NT, Ghaemmaghami S, Newman JRS, Weissman JS. Genome-wide analysis
717 in vivo of translation with nucleotide resolution using ribosome profiling. *Science*.
718 American Association for the Advancement of Science; 2009;324: 218–223.
719 doi:10.1126/science.1168978
- 720 36. Kim H, Certa U, Döbeli H, Jakob P, Hol WG. Crystal structure of fructose-1,6-
721 bisphosphate aldolase from the human malaria parasite *Plasmodium falciparum*.
722 *Biochemistry*. 1998;37: 4388–4396. doi:10.1021/bi972233h
- 723 37. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific
724 ligands. *Nature*. 1990;346: 818–822. doi:10.1038/346818a0
- 725 38. Stoltenburg R, Reinemann C, Strehlitz B. FluMag-SELEX as an advantageous
726 method for DNA aptamer selection. *Anal Bioanal Chem*. 2005;383: 83–91.
727 doi:10.1007/s00216-005-3388-9
- 728 39. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image
729 analysis. *Nature Methods*. 2012;9: 671–675. doi:10.1038/nmeth.2089
- 730 40. Duhr S, Braun D. Why molecules move along a temperature gradient. *Proceedings*
731 *of the National Academy of Sciences*. 2006;103: 19678–19682.
732 doi:10.1073/pnas.0603873103
- 733 41. Dhont JKG, Wiegand S, Duhr S, Braun D. Thermodiffusion of charged colloids:
734 single-particle diffusion. *Langmuir*. 2007;23: 1674–1683. doi:10.1021/la062184m
- 735 42. Breitsprecher D, Schlinck N, Witte D, Duhr S, Baaske P, Schubert T. Aptamer
736 Binding Studies Using MicroScale Thermophoresis. *Methods Mol Biol*. New York,
737 NY: Springer New York; 2016;1380: 99–111. doi:10.1007/978-1-4939-3197-2_8
- 738 43. Hianik T, Ostatná V, Sonlajtnerova M, Grman I. Influence of ionic strength, pH and
739 aptamer configuration for binding affinity to thrombin. *Bioelectrochemistry*.
740 2007;70: 127–133. doi:10.1016/j.bioelechem.2006.03.012
- 741 44. Bell D, Peeling RW, WHO-Regional Office for the Western Pacific/TDR.
742 Evaluation of rapid diagnostic tests: malaria. *Nature reviews. Microbiology*. 2006.
743 pp. S34–8. doi:10.1038/nrmicro1524
- 744 45. Kaur H, Sehgal R, Kumar A, Sehgal A, Bansal D, Sultan AA. Screening and
745 identification of potential novel biomarker for diagnosis of complicated *Plasmodium*

- 746 vivax malaria. *Journal of Translational Medicine*. BioMed Central; 2018;16: 42.
747 doi:10.1186/s12967-018-1646-9
- 748 46. Meerstein-Kessel L, van der Lee R, Stone W, Lanke K, Baker DA, Alano P, et al.
749 Probabilistic data integration identifies reliable gametocyte-specific proteins and
750 transcripts in malaria parasites. *Sci Rep*. Nature Publishing Group; 2018;8: 410.
751 doi:10.1038/s41598-017-18840-7
- 752 47. Frith K-A, Fogel R, Goldring JPD, Krause RGE, Khati M, Hoppe H, et al. Towards
753 development of aptamers that specifically bind to lactate dehydrogenase of
754 *Plasmodium falciparum* through epitopic targeting. *Malar J*. 2018;17: 191.
755 doi:10.1186/s12936-018-2336-z
- 756 48. Rousu J, Agranoff DD, Sodeinde O, Shawe-Taylor J, Fernandez-Reyes D.
757 Biomarker discovery by sparse canonical correlation analysis of complex clinical
758 phenotypes of tuberculosis and malaria. Price ND, editor. *PLoS Comput Biol*.
759 2013;9: e1003018. doi:10.1371/journal.pcbi.1003018
- 760 49. Kumar K, Singal A, Rizvi MMA, Chauhan VS. High mobility group box (HMGB)
761 proteins of *Plasmodium falciparum*: DNA binding proteins with pro-inflammatory
762 activity. *Parasitol Int*. 2008;57: 150–157. doi:10.1016/j.parint.2007.11.005
- 763 50. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger
764 signaling. *Mol Med*. 2008;14: 476–484. doi:10.2119/2008-00034.Klune
- 765 51. Briquet S, Lawson-Hogban N, Boisson B, Soares MP, Péronet R, Smith L, et al.
766 Disruption of Parasite hmgb2 Gene Attenuates *Plasmodium berghei* ANKA
767 Pathogenicity. *Infection and Immunity*. 2015;83: 2771–2784.
768 doi:10.1128/IAI.03129-14
- 769 52. Nimjee SM, White RR, Becker RC, Sullenger BA. Aptamers as Therapeutics. *Annu*
770 *Rev Pharmacol Toxicol*. 2017;57: 61–79. doi:10.1146/annurev-pharmtox-010716-
771 104558
- 772 53. Cheung Y-W, Dirkzwager RM, Wong W-C, Cardoso J, D'Arc Neves Costa J, Tanner
773 JA. Aptamer-mediated *Plasmodium*-specific diagnosis of malaria. *Biochimie*.
774 2018;145: 131–136. doi:10.1016/j.biochi.2017.10.017
- 775 54. Miranda GF, Feng L, Shiu SC-C, Dirkzwager RM, Cheung Y-W, Tanner JA, et al.
776 Aptamer-Based Electrochemical Biosensor for Highly Sensitive and Selective
777 Malaria Detection with Adjustable Dynamic Response Range and Reusability.
778 *Sensors & Actuators: B Chemical*. Elsevier B.V; 2017;: 1–23.
779 doi:10.1016/j.snb.2017.07.117
- 780 55. Hamaguchi N, Ellington A, Stanton M. Aptamer beacons for the direct detection of
781 proteins. *Anal Biochem*. 2001;294: 126–131. doi:10.1006/abio.2001.5169

- 782 56. Gawande BN, Rohloff JC, Carter JD, Carlowitz von I, Zhang C, Schneider DJ, et al.
783 Selection of DNA aptamers with two modified bases. *Proc Natl Acad Sci USA*.
784 2017;114: 2898–2903. doi:10.1073/pnas.1615475114
- 785 57. Abeydeera ND, Egli M, Cox N, Mercier K, Conde JN, Pallan PS, et al. Evoking
786 picomolar binding in RNA by a single phosphorodithioate linkage. *Nucleic Acids*
787 *Research*. 2016;44: 8052–8064. doi:10.1093/nar/gkw725
- 788






Figure 1


A




B



C



D



E




Figure 2




Figure 3






Figure 4

A**B****C****Figure 5**